ReviewCancerandCentralNervousSystemTumorSurveillanceinPediatricNeuroﬁbromatosis1D.GarethR.Evans1,2,HectorSalvador3,VivianY.Chang4,5,6,AyeletErez7,StephanD.Voss8,KamiWolfeSchneider9,HamishS.Scott10,SharonE.Plon11,andUriTabori12,13AbstractAlthoughtheneuroﬁbromatosesconsistofatleastthreeauto-somaldominantlyinheriteddisorders,neuroﬁbromatosis1(NF1),neuroﬁbromatosis2(NF2),andschwannomatosis,NF1representsamultisystempleiotropicconditionverydifferentfromtheothertwo.NF1isageneticsyndromeﬁrstmanifestinginchildhood;affectingmultipleorgans,childhooddevelopment,andneurocognitivestatus;andpresentingtheclinicianwithoftencomplexmanagementdecisionsthatrequireamultidisciplinaryapproach.Moleculargenetictesting(seearticlefordetaileddis-cussion)isrecommendedtoconﬁrmNF1,particularlyinchildrenfulﬁllingonlypigmentaryfeaturesofthediagnosticcriteria.AlthoughcancerriskisnotthemajorissuefacinganindividualwithNF1duringchildhood,theconditioncausessigniﬁcantlyincreasedmalignancyriskscomparedwiththegeneralpopula-tion.Speciﬁcally,NF1isassociatedwithhighlyelevatedrisksofjuvenilemyelomonocyticleukemia,rhabdomyosarcoma,andmalignantperipheralnervesheathtumoraswellassubstantialrisksofnoninvasivepilocyticastrocytoma,particularlyopticpathwayglioma(OPG),whichrepresentamajormanagementissue.Until8yearsofage,clinicalassessmentforOPGisadvisedevery6to12months,butroutineMRIassessmentisnotcurrentlyadvisedinasymptomaticindividualswithNF1andnosignsofclinicalvisualpathwaydisturbance.Routinesurveillanceforothermalignanciesisnotrecommended,butcliniciansandparentsshouldbeawareofthesmallrisks(<1%)ofcertainspeciﬁcindividualmalignancies(e.g.,rhabdomyosarcoma).Tumorsdocontributetobothmorbidityandmortality,especiallylaterinlife.Asinglewhole-bodyMRIshouldbeconsideredattransitiontoadulthoodtoassistindeterminingapproachestolong-termfollow-up.ClinCancerRes;23(12);e46–e53.Ó2017AACR.Seeallarticlesintheonline-onlyCCRPediatricOncologySeries.IntroductionTheneuroﬁbromatoses,includingneuroﬁbromatosis1(NF1),neuroﬁbromatosis2(NF2),andschwannomatosis,haveformostoftheirknownexistencebeenlumpedtogetherasasingleentity.ThiswaslargelyduetothesigniﬁcantinﬂuenceoftherenownedneurosurgeonHarveyCushing,whodescribedthatbilateraleighthnervetumorswerepartofvonReckling-hausendiseaseintheearly20thcentury(1).TheclinicalandgeneticdistinctionbetweenNF1andNF2wasnotfullyrecog-nizeduntilthepastthreedecades,andinpriorreports,NF1andNF2werefrequentlyreferredtointerchangeably(2).Gradually,beginninginthelatter20yearsofthe20thcentury,thediffer-encesinclinicalpresentationandgeneticetiologyresultedinthedeﬁnitionoftwodistinctconditions,NF1,formerlyvonRecklinghausenneuroﬁbromatosis,andNF2,previouslybilat-eralacoustic/centralneuroﬁbromatosis.Theconditionswereeventuallyrecognizedasdistinctandseparatemolecularenti-ties,withthelocalizationoftheirrespectivegenestochromo-somes17qand22q(3,4),andsubsequentlyandformally,clinicallydelineatedatanNIH(Bethesda,Maryland)consensusmeetingin1987(5).Thegeneanddisease-associatedmutationsforNF1wereidentiﬁedin1990(6)andforNF2in1993(7–9).EvidenceconsistentlysuggeststhatclassicalNF1andNF2fulﬁllingNIHcriteriaarebothheterogeneousconditions.ThereareadditionalconditionswithphenotypicoverlapwithclassicNF1and/orNF2.Familieswithmultiplecafeaulait(CAL)maculesandmacrocephalywithoutneuroﬁbromasorothertypicalNF1featuresmayhaveeitherathreebase-pairdeletion(c.2970_2972delAAT)inNF1(10)oraSPRED1mutation(11),andathirdtypeofneuroﬁbromatosiscalledschwanno-matosisisnowaccepted(12–14),withclinicalandtumorfeaturesthatoverlapwithNF2.Recommendationsfortumorsurveillanceofgenecarriersandmembersofsyndromicfamiliesarebaseduponreviewoftheliteratureanddiscussioninthe2016AACRChildhoodCancerPredispositionWorkshop.1ManchesterCentreforGenomicMedicine,UniversityofManchester,Manche-ster,UnitedKingdom.2ManchesterAcademicHealthScienceCentre,SaintMary'sHospital,CentralManchesterUniversityHospitalsNHSFoundationTrust,Manchester,UnitedKingdom.3DepartmentofPediatricOnco-HematologyandDevelopmentalTumorBiologyLaboratory,HospitalSantJoandeDeu,Barce-lona,Spain.4DepartmentofPediatrics,DivisionofPediatricHematology-Oncol-ogyChildren'sDiscoveryandInnovationInstitute,UniversityofCalifornia,LosAngeles,California.5JonssonComprehensiveCancerCenter,UniversityofCalifornia,LosAngeles,California.6DavidGeffenSchoolofMedicine,LosAngeles,California.7WeizmannInstituteofScience,Rehovot,Israel.8Depart-mentofRadiology,BostonChildren'sHospital,HarvardMedicalSchool,Boston,Massachusetts.9Hematology,Oncology,andBoneMarrowTransplant,Univer-sityofColoradoDenver,Children'sHospitalColorado,Aurora,Colorado.10DepartmentofGeneticsandMolecularPathology,CentreforCancerBiology,anSAPathology&UniSAalliance,Adelaide,Australia.11DepartmentofPediat-rics,BaylorCollegeofMedicineandTexasChildren'sHospital,Houston,Texas.12DivisionofHaematology/Oncology,UniversityofToronto,Toronto,Ontario,Canada.13ResearchInstituteandTheArthurandSoniaLabattBrainTumourResearchCentre,TheHospitalforSickChildren,Toronto,Ontario,Canada.CorrespondingAuthor:D.GarethR.Evans,UniversityofManchester,OxfordRoad,ManchesterM139WL,UnitedKingdom.Phone:161-276-6206;Fax:161-276-6145;E-mail:gareth.evans@cmft.nhs.ukdoi:10.1158/1078-0432.CCR-17-0589Ó2017AmericanAssociationforCancerResearch.CCRPEDIATRICONCOLOGYSERIESClinCancerRes;23(12)June15,2017e46on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from NF1ClinicalmanifestationsDiagnosticcriteria.TheNIHdiagnosticcriteriaforNF1areshowninTable1(5).Whenthesecriteriaareused,misdiagnosisorconfusionisunlikelyunlessadiagnosisismadebasedononlypigmentarycriteria.Patientswithsegmentalneuroﬁbromatosis(neuroﬁbromatosisfeatureslimitedtooneareaofthebody)canfulﬁllthesecriteria,andcliniciansshouldnoteanysegmentalinvolvement,asthismaymeanthechildhasapartialor"mosaic"formofNF1.Cliniciansneedtobeawarethatasubsetofindi-vidualsandfamilieswithmultipleCALmacules,withoutotherNF1primaryfeatures,mayhavemutationsintheSPRED1gene,aconditioncalledLegiussyndrome(11).Furthermore,patientswithconstitutionalmismatchrepairdeﬁciencysyndrome(CMMRD)canfulﬁllthecriteriaforNF1buthaveaverydifferentcancerspectrumandmuchhighercancerpenetrance[seetheCCRPedi-atricOncologySeriesarticlebyTaboriandcolleagues(15)].AhighindexofsuspicionforCMMRDisrecommendedinchildrenwithNF1featureswhoarefromconsanguineousfamilies,havethecancerstypicalofCMMRD(i.e.,high-gradeglioma,colorectalpolypsandcarcinoma,andhematopoieticmalignancies,especial-lyacutelymphoidleukemiaandlymphoma),and/orhavefamilyhistoryofcancersuggestiveofLynchsyndrome,and/orlackthecharacteristicdevelopmentalissuestypicallyseeninNF1.NF1clinicalfeaturesNF1clinicalfeaturesincludesomeofthediagnosticcriteriacategories(Table1).Inchildhood,CALmaculesaresmall,asreﬂectedinthediagnosticcriteria,buttheybecomelargerandoftenmergeasindividualsage.Theytypicallyhavealinearratherthanragged-edgeborderandareoftendescribedassimilartothe"coastofCalifornia"incontrasttothe"coastofMaine"appearanceobservedinindividualswithMcCune–Alb-rightsyndromeorCMMRD.TheCALmaculesinNF1oftenfadeinlaterlifeandmaybelesseasytorecognizewithoutaWood'slight/lamp.CALmaculesareﬂatwithnoassociatedhairandhavenopropensityformalignanttransformation.Frecklingusuallyoccursinnon–sun-exposedskin,withtheaxillamorefrequentlyaffectedthanthegroin.FrecklingusuallyappearslaterthantheCALmacules.NeuroﬁbromasonandundertheskinarethecharacteristicfeatureofNF1.Theseoftenstartaspinkish-purple,raised,softlesionsthatcanthentrans-formintomore"wart"-likegrowths.Plexiformtumors,whichlikelyrepresentanearlyembryonicorigintumor,areoftenvisiblefrombirthwithdiffuseinvolvementoftheskinandunderlyingstructures.Approximately2%to3%ofpatientswithNF1haveunsightlyplexiformtumorsaffectingtheheadandneck(16,17).Theoverlyingskinisoftenhyperpigmentedandloseselasticity,leadingtoagravityeffectof"sagging"ofthetumor.Subcutaneousnodulartumorsoccurasgrowthsonperipheralnerves,whichareseparatefromtheoverlyingskin.Thesetumorsmayappearasfusiformswellingsonmoremajornerveroutesandcanbepainfultothetouch.Thedeeperfusiformsubcutaneousandplexiformtumorsmayundergomalignantchangetomalignantperipheralnervesheathtumor(MPNST).Althoughthisisuncommoninchildhood,malig-nanttransformationcanoccurbeginninginadolescenceandveryrarelyearlier(Table2).TheappearanceofirisLischnodules(benignhamartomas)typicallyoccursearlyinchild-hoodandusuallyprecedestheappearanceofcutaneousneu-roﬁbromas.Lischnodulesofmelanocyticoriginappearaslightbrownish-orangeout-swellingsfromthelatticeworkoftheiris,incontrasttoirisnevi,whichareﬂatandusuallydarkbrownorblack.Ophthalmicexaminationbyslitlampis,therefore,ausefuldiagnosticaidinequivocalcases.Anothercommonfeatureinchildhoodarespotsontheskincalledxanthogra-nulomasthatareself-limiting.Theyusuallyappearbetween2and6yearsofage,disappearingwithinayear,andhavebeenlinkedtoanapparentincreasedriskofleukemia,(18)althoughthisassociationisnottotallycompelling.GeneticsandepidemiologyAnumberofstudieshaveaddressedthegenetics,prevalence,andincidenceofNF1(19).Theautosomaldominantinheri-tancepatternofNF1hasbeenconﬁrmedformanyyears(2).Atleast50%ofcasespresentasdenovomutationsofthegeneandappearasisolatedcases.NF1hasabirthincidenceofonein1,900to2,800(20,21)andadiagnosticprevalenceofonein4,150to4,950(20,21).Theprevalenceislowerthanbirthincidenceduetoundiagnosedcasesinpopulationsandanearliermeanageatdeath.ThehighestfrequencywasreportedinanIsraelistudyofmilitaryrecruits,withaprevalenceofaroundoneper1,000(22);however,thiswasbasedlargelyonthepresenceofCALmaculesandcouldrepresentafoundereffectforathreebase-pairdeletioninNF1oraSPRED1mutation(10,11,20).NearlyallchildrenwhoinheritanNF1mutationfromtheirparentcanbediagnosedonthebasisofpigmentaryfeaturesinveryearlychildhood;however,clinicaldiagnosisindenovocasesmaytakelonger.Indeed,recentmolecularevidenceshowsthatalthoughthesensitivityforNF1mutationdetectionbasedonRNAanalysisisaround96%(23–26),childrenmeetingNIHcriteriabasedsolelyonpigmentaryfeatures(e.g.,6CALmacules)onlyappeartohaveapprox-imatelya67%chanceofhavingNF1versus8%to10%havingLegiussyndrome(26).Fortheremainderofindividualsmeet-ingsomecriteria,particularlythosewithmoreragged-edgeCALpatchesandahistoryofmalignantcancers,considerationshouldbegiventoCMMRD,asthediagnosesmaybeconfusedgiventheoverlappingNIHcriteriaandsimilartumorspectrum[e.g.,neuroﬁbromaandopticpathwayglioma(OPG);ref.27].OtherconditionssuchasLEOPARDsyndrome(Noonansyn-dromewithmultiplelentigines)andotherRASopathiesmayalsopresentwithpigmentaryfeaturesmimickingNF1.ClinicalcourseandchildhoodtumorriskNF1iswidelyvariableinitsclinicalcourse.ThisvariationisfrequentlygreatevenwithinfamilieswithanidenticalNF1mutation(28).Assuch,predictingdiseaseseverityisdifﬁcult.Childrenwithearlymanifestationsofamoreseverediseasecourse,suchasmultipletumors,mayhaveundergonelossinearlydevelopmentofthewild-typeNF1allele,haveaTable1.DiagnosticcriteriaforNF1(twoormoremustbepresent)1.SixormoreCALmacules,thegreatestdiameterofwhichismorethan5mminprepubertalpatientsandmorethan15mminpostpubertalpatients2.Twoormoreneuroﬁbromasofanytype,oroneplexiformneuroﬁbroma3.Axillaryoringuinalfreckling4.Opticglioma5.TwoormoreLischnodules6.Adistinctiveosseouslesionsuchassphenoiddysplasiaorpseudarthrosis7.Aﬁrst-degreerelativewithNF1accordingtotheprecedingcriteriaNeuroﬁbromatosis1www.aacrjournals.orgClinCancerRes;23(12)June15,2017e47on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from constitutionalwholegermlinedeletionoftheNF1gene,orinheritedapatternofmodiﬁergenesthatalterthephenotype(28).Diagnosisofoneclinicalfeaturedoesnotusuallyimplyahighriskofanothercomplication,althoughthereareexceptions.Forexample,OPGisassociatedwithahigherriskofsymptomaticgliomasoccurringelsewhereinthebrain(oftenlaterinchild-hood;ref.29),andthepresenceofmultiplesubcutaneousperiph-eralnerveneuroﬁbromasincreasestheriskofMPNST(30–32).LargestudiesinwhichchildrenwithNF1havebeenscreenedwithMRIscansindicatethatapproximately15%haveatleastaunilateralOPG(33).ItisunclearhowmanychildrenwhohaveanOPGdetectedbysurveillanceimagingwilleverdevelopsymp-toms,asstudiesthathavenotspeciﬁcallyscreenedusingimagingﬁndmuchlowerratesofbetween0.7%and6%(16,17,29).SymptomaticOPGsusuallypresentbetweenbirthand6yearsofage,peakingataround3to4yearsandhavingamorebenigncoursethansporadicOPG(33,34).However,adultonsetofsymptomsdoesoccur.Brainstemgliomasarelessfrequentandaffectapproximately1%to2%ofpatientsbutaremorefrequentinthosewithopticglioma(Table2;ref.29).Approximately2%ofindividualswithNF1presentwithsymptomsfromspinaltumorsthatrequiresurgery,butonMRIimaging,morethan60%appeartohavespinalnerverootinvolvementinadulthood(27).Itisnotclearwhysofewspinaltumorspresentsymptomatically,whichisincontrasttoNF2.Othernonneoplastic,NF1-associatedcentralnervoussystem(CNS)lesionsincludemacrocephaly(45%withheadcircumference>97thpercentile),aqueductstenosis(<1%),andneuroﬁbromatosis-associatedwhitemattertractenhance-mentorvacuolationchangesonT2-weightedMRI(33%–78%;refs.35–37).MalignanciesinNF1.MPNSTMPNSTisararetumoroccurringinonlyonepermillionannuallyinthegeneralpopulation,andbetween20%and50%ofpatientswithMPNSTshaveNF1(38),withNF1patientshavingan8%to12%lifetimerisk(38,39).MPNSTsarerareinchildhood,andarapidlygrowingdeep-seatedtumorwithpainorneurologicdeﬁcitneedstobeinvestigated.MRIoftenshowsaheterogenoustumor,and18F-FDGPETimag-ingisusefulindifferentiatingabenignplexiformtumorfrommalignantchange,withanumberofstudiesshowingincreasedFDGuptakeassociatedwithMPNST(39–41).Indeed,FDGPET/CT–guidedbiopsyhasbeenadvocatedasameansofincreasingthelikelihoodofobtainingaccuratebiopsyspecimensinpatientswithlargeplexiformneuroﬁbromas(42)."Atypicalneuroﬁbro-mas"areatransitionphasefromapurebenignnodularplexiformneuroﬁbromatoMPNST.NotallatypicalneuroﬁbromaswilleventuallydevelopintoMPNST,butthereisanincreasedrisk,andthesetumorsshouldbeconsideredpremalignantlesions.Atotal-bodyMRIisabletoidentifynodularneuroﬁbromaswithanincreasedgrowthratesuspectedofatypicalneuroﬁbroma.Indi-vidualswithNF1withanatypicalneuroﬁbromatendtohavemorethanoneatypicalneuroﬁbroma,andasagroup,theseindividualshaveahighriskofdevelopingMPNSTs.GliomasHigh-gradegliomasoccuratincreasedfrequencyinNF1andareoftenassociatedwiththepresenceofanopticglioma(29).Overall,theyoccurin<1%ofpatients(22,27),andduetotheirrarity,achildwithNF1andhigh-gradegliomashouldbeinves-tigatedforCMMRDifanNF1mutationhasnotbeenpreviouslyidentiﬁed.JuvenilemyelomonocyticleukemiaJuvenilemyelomonocyticleuke-miaisadeﬁnitiveNF1complication.Itisgenerallythoughttobeincurableexceptbyautologousbonemarrowtransplantationbutoccursinonlyaboutonein300NF1patients(43),withnoneoccurringinonelargepopulation–basedseriesof1,404patientswithNF1(44).Embryonalrhabdomyosarcoma(eRMS)AlthoughtheprevalenceofembryonalrhabdomyosarcomainNF1populationshadbeenestimatedashighas1.4%to6%,largerseriesconﬁrmariskoflessthan1%(17,45,46)butstillhigherthaninthegeneralpopu-lation.Theurogenitalsystemisthemostcommonanatomicsiteinvolved,althoughotherlocalizationshavebeenreported(orbitisthesecondmostfrequentlocalization).eRMSinNF1patientsarecharacterizedbyparticularlyearlyonset(0–5years)Table2.NF1:tumorfeatures,withtypicalagesatpresentationandchildhoodriskDiseasefeatureFrequency(pediatricrisk)in%AgeofpresentationSeriesHuson(15)McGaughran(16)UpdateforkeytumorsaPatientsinseries1355231,500Peripheralneuroﬁbromas>9960(20–60)7yearsPlexiformneuroﬁbromasAllplexiforms3015(15)0–18yearsLargelesionsofheadandneck1.26(6)0–3yearsCNStumorsOpticglioma(symptomatic)1.55(5–6)6%ChildhoodOtherCNStumors1.52.0(1)2%LifelongSpinalneuroﬁbromas1.52.0(0.2)0.2%LifelongMalignancyMalignantperipheralnervesheathtumors1.55(0.2)0.2%bLifelongEmbryonalrhabdomyosarcoma1.50.2(0.2)0.3%0–5Gastrointestinaltumorsc(neuroﬁbromasandGISTs)2.22.0(0)0%LifelongPheochromocytoma0.70.4(0.2)0%10yearsDuodenalcarcinoid1.52(0.1)0%10yearsGlomustumorsinnailbeds00.2(0.1)0%Adults(usually)Abbreviation:GIST,gastrointestinalstromaltumor.aUpdatebasedon1,500NF1patientsintheManchesterregister.b0.5%byage20years.cFrequencyofGISTinadulthoodhasbeenfoundtobeashighas6%,butthismayreﬂectMRIsurveillancedetectingasymptomatictumors.CCRPEDIATRICONCOLOGYSERIESClinCancerRes;23(12)June15,2017ClinicalCancerResearche48on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from andmalesexpredominance.Allthecasesreportedarehistolog-icallyembryonaltype.Theprognosisandoverallsurvivalareequivalenttonon-NF1eRMS.Becauseoftheirlocation,eRMSinNF1aretypicallysymptomaticatpresentation,andtogetherwiththegoodprognosisandlowincidenceinNF1populations,thereareinsufﬁcientdatatorecommendanyroutinescreeningforeRMS.EndocrinetumorsandothertumorsDuodenalendocrine(carcinoid)tumorsandpheochromocytomaoccurinNF1withafrequencyofaround1%(Table2),buttheyarerareinchildhood."Glomus"tumorscanoccuraspainfulswellingsinthenailbedsandarebeingincreasinglyrecognized(47).Gastrointestinalstromaltumorswerepreviouslycalledgastrointestinalneuroﬁbromasandoccursymptomaticallyinaround2%ofpatientswithNF1butagain,rarelyinchildhood.Previousguidelines.GuidelinesformanagementofNF1havebeenpublishedbyseveraldifferentprofessionalorganiza-tionsandconcentrateonthediagnosisandmanagementofOPG(48–51).GeneticSummaryTheNF1geneonchromosome17qistheonlyknowngenetocausetypicalNF1.Thegenecontains62codingexonsspreadover282kb.TherearemultipleNF1pseudogenesinthegenomethatcancomplicatemutationanalysis.ItproducesmultiplemRNAandproteinisoformsbyalternativesplicingandalsobyRNAediting.TheNF1geneencodesneuroﬁbromin,alarge2,839aminoacidcytoplasmicproteinthatispredom-inantlyexpressedinneurons,Schwanncells,oligodendrocytes,lung,colon,muscle,andleukocytes(19).Themultidomainproteinregulatesseveralintracellularprocesses,includingtheRAS/ERK/MAPkinasecascadeandcytoskeletalassembly.Mostdescribedmutationsresultintruncatedproteinsandarespreadthroughoutthegene.LossoffunctionofbothallelesoftheNF1tumorsuppressorgeneleadstolossoftheNF1protein(neu-roﬁbromin)inthecausativeprecursorcell.ThiscauseslossoftumorsuppressorfunctionleadingtoahighriskoftumordevelopmentduetodecreasedRASsignalinginhibitionand,hence,toincreasedproliferation,particularlyincellsofneuralcrestorigin.NF1isautosomaldominantlyinheritedwithvirtuallycom-pletebutvariablepenetrance.Theﬁrstgenotype–phenotyperelationshipreportedwasbasedonwholegenedeletions(48).Theselargedeletionsoccurin2%to7%ofindividualswithNF1andareassociatedwithlargerbodysize,intellectualdisability,andgreatertumorburdenaswellasa2-to3-foldgreaterriskofMPNST(23–26,52).OtherclearcorrelationswerereportedlaterwithcertainnontruncatingmutationsbeingassociatedwithamilderformofNF1(26,53–55).Inparticular,anin-framedeletion(c.2970_2972delAAT;ref.53)appearstocauseaCALmacules–onlytypeofNF1withouttumorrisk,similartoSPRED1causingLegiussyndrome(11).Othermis-sensemutations(particularlyatresiduep.Arg1809)causeaNoonan-likeassociationwithpulmonarystenosis(54,55),whereascertainmissensemutationscauseaseverespinalformofNF1characterizedbyabsenceofpigmentaryfeatures,leadingtodiagnosticchallengesinchildhoodduetorelativeabsenceofCALmacules(56).GenetictestingrecommendationsTheclinicalcriteriafordiagnosingNF1havehistoricallybeenbasedonmeetingtwoormoreofthecriterialistedinTable1.Previously,NF1moleculartestingwasnotroutinelyrecom-mendedunlessneededforreproductivedecisionmakinginpatientswithaclinicaldiagnosisofNF1,asmoleculardiag-nosiswouldnotaltermanagementforindividualswithanestablishedclinicaldiagnosis.Thisclassicparadigmisshifting,however,basedonnewknowledgethatavarietyofsyndromeshaveoverlappingfeatureswithNF1butaverydifferentclinicalcourseandontheemergingtherapeuticbeneﬁtsobservedwithtargetedtherapiesaimedattheRAS/MAPKpathwayinchildrenwithNF1(57).Achildwhomeetsoneormoreclinicalcriterion(asoutlinedinTable1)shouldnowhaveNF1moleculargenetictesting(sequencinganddeletion/duplicationanalysis)offeredtoconﬁrmifNF1isthecorrectdiagnosis,asamisdi-agnosiscouldleadtoinappropriatesurveillance.AmutationwillbedetectedonRNAanalysisin67%ofindividualswhomeetpigmentary-onlycriteriaandapproximately95%to96%whomeetclinicaldiagnosticcriteria(23–26).Ifamutationisnotdetected,however,severalotherconditions,somewithcancerriskassociatedandotherswithout,maybecontributingtothephenotype.Someexamplesincludepigmentaryabnor-malitiesduetomutationsinSPRED1,CMMRDduetobiallelicTable3.Summaryofrecommendationsforchildhoodmanagement1.GenetictestingChildrenconsideredatriskofNF1especiallywith6þCALmaculesordiagnosedwithNIHcriteriashouldideallyhavegenetictestingoftheNF1genewithanRNA-basedapproachandtestingofSPRED1ifpigmentaryfeaturesonly2.GenetictestingThosetestingnegativeshouldbeconsideredforapanelofgenesincludingGNAS,MLH1,MSH2,MSH6,NF2,PMS2,PTPN11,SOS1,andSPRED1(ifnotalreadytested)3.GeneralAnnualhistoryandphysicalexam(includingskinandneurologicexamandalsobloodpressure,height,weight,andpubertaldevelopment)Tumorsurveillance4.OPGChildrenwithNF1shouldhave6–12monthlyophthalmicassessmentsfrombirthto8years.Onebaselineassessmentofcolorvisionandvisualﬁeldsshouldbeundertakenwhenthechildisdevelopmentallyable.5.MPNSTAssesswithhistoryandclinicalexaminationannuallyfortypicalsignsofMPNST:anynondermalneuroﬁbromawithrapidgrowth,lossofneurologicfunction,orincreasingpainorchangeinconsistency6.JMMLAssessforriskofJMMLinNF1inchildrenwithjuvenilexanthogranulomas7.InternalburdenAbaselinewhole-bodyMRIshouldbeconsideredbetweenages16and20yearstoassessinternaltumorburdentodetermineadultfollow-upregimen8.RoutineMRIMRIsurveillanceisnotcurrentlyrecommendedunlesssymptomaticorwithanalreadydiagnosedtumor.Speciﬁcbiochemicalorimagingsurveillancefortumorswithabsoluterisksinchildhoodbelow1%isnotrecommendedsuchasforpheochromocytoma,neuroendocrinetumors,MPNST,ornon-opticglioma.Abbreviation:JMML,juvenilemyelomonocyticleukemia.Neuroﬁbromatosis1www.aacrjournals.orgClinCancerRes;23(12)June15,2017e49on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from MLH1,MSH2,MSH6,orPMS2mutations(58),RASopathysyndromes(suchasLEOPARD/Noonan)duetomutationsinPTPN11,orMcCune–AlbrightsyndromeduetomutationsinGNAS(Table3;refs.11,27,59).GiventhepredominanceofNF1andLegiussyndromeastheunderlyingdiagnoses,mostcentersbegingenetictestingwiththeNF1andSPRED1genes(Fig.1).Ifnegative,thenconsiderationofalargerpanelorwhole-exomeanalysisisundertaken.Forcoun-triesinwhichpanelanalysisisavailable,theprimaryconcernsdiscussedbytheworkshopcommitteewere2-fold.First,initiatingﬁrst-tiertestingwithapanelthatincludesNF1andSPRED1ispreferredpriortomovingontoalargerpanelthatmightresultinincidentalﬁndingofsingleheterozygousmismatchrepairmuta-tionsassociatedwithadult-onsetLynchsyndromeinchildhoodunrelatedtothechild'sphenotype.Second,predictivegenetictestingforadultonsetconditionsgenerallyshouldbedeferredunlessaninterventioninitiatedinchildhoodmayreducemor-bidityormortality(59,60).IfanNF1orSPRED1mutationisnotdetected,however,theriskofidentifyingLynchsyndromeisoutweighedbythepotentialbeneﬁtofearlyCMMRDdetectioninthissubpopulation.Ingeneral,foranyhereditarygenepanel,thelikelihoodofidentifyingvariantsofuncertainsigniﬁcance(VUS)increasesasmoregenesareevaluated,withmanypanelstudiesinadultsresultinginonaveragemorethanoneVUSperpaneltestreported(61).ByonlypursuingpanelsinchildrenwithoutamoleculardiagnosisofNF1,fewerpatientswillhavetheuncer-taintyofVUSthanifallpatientspursuedpaneltestinginclud-ingNF1asaﬁrsttier.Therefore,werecommendthealgorithmpresentedinFig.1.Ideally,NF1genetictestingshouldbeperformedonlymphocytesusingacombinedDNA/RNA–basedapproach.Ifnomutationisdetectedinisolatedcases,testingforNF1mutationsfrommela-nocyteculturesfromatleasttwopigmentarylesionsmaybeconsideredtoevaluateformosaicism,especiallyintheabsenceoffamilyhistoryofclinicalfeaturesofNF1.Priortopanel/exometesting,childrencouldbereferredtosubspecialtyclinicsifnotalreadyinoneandthenproceedtoadditionaltesting.Cancer/TumorScreening/SurveillanceProtocolsOPGdoesnotaffectoverallsurvivalofchildrenwithNF1(unlikeinchildrenwithsporadicOPG;ref.34),andlittleisknownaboutthenaturalhistoryofOPG.Nonetheless,thereisaclearneedtomakeanearlydiagnosisofOPGbeforesignif-icantlossofvisionoccurs.AsthegreatestriskofdevelopingOPGisduringchildhood(especiallyinchildren<7yearsofNo pathogenic mutation detectedPathogenic mutation detectedNo further/reﬂex testing*Panel/exome testing should include**CMMRD genes AND melanocytetesting of pigmentary lesion shouldbe considered in isolated casesClinical feature(s) of NF1:NF1 sequencing anddeletion/duplication analysis© 2017 American Association for Cancer ResearchFigure1.SummaryofexpertrecommendationsforgenetictestingandclinicalmanagementofNF1.,Next-generationsequencingpanel/focusedexomeshouldincludeatleastGNAS,MLH1,MSH2,MSH6,NF2,PMS2,PTPN11,SOS1,andSPRED1(ifnotalreadytested)andeitherreﬂexto,orinclude,deletion/duplicationanalysisofeachgene.SPRED1canbetestedasacombinedﬁrst-linetestwithNF1inthosechildrenwithpigmentary-onlycriteria.Alternatively,thoseisolatedcaseswithpigmentary-onlyphenotypecouldbetestedforapanel/exomeﬁrstincenterswithsufﬁcientexpertisetointerpretandcommunicatevariantsofuncertainsigniﬁcance,particularlyiftheCALmaculesarenottypicalforNF1(raggededges).Ifnomutationisdetectedonpanel/exome,however,RNAtestingforNF1maystillberequired,asDNA-basedapproachesarelesssensitive.,CMMRDgenes:MLH1,MSH2,MSH6,PMS2.Notethat(i)ifCMMRDisstronglysuspected,PMS2isnotcoveredwellinmostpanels,and(ii)CMMRDgenesmaybeexcludedfrompanelswhenfamilyhistoryclearlysuggestsdominantinheritanceoffeaturestoreducethechanceofanincidentalﬁndingofLynchsyndromeinchildhood.CCRPEDIATRICONCOLOGYSERIESClinCancerRes;23(12)June15,2017ClinicalCancerResearche50on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from age),ophthalmologicexamsshouldstartwhentheNF1diag-nosisisestablishedandcontinuethroughoutchildhood.Thesecandetectbothvisuallossandchangesovertimethatwillrequiretherapy.AlthoughthegoldstandardforthediagnosisofanOPGisMRI,earlydetectionofanasymptomaticOPGhasnotbeenproventoreducetheincidenceofvisualloss,nordoesaninitialnormalMRIexcludethedevelopmentofasubsequentOPG.AstreatmentforanOPGisnotrequiredintheabsenceofpro-gressivevisualdisturbanceorproptosis,mostpreviousproto-colsdonotrecommendroutinescreeningbyMRI,asthiswouldneedtobecarriedoutfrequently,oftenrequiringsedation,andasmanyastwothirdsoftheOPGswouldneverbecomesymptomatic(48–50).Newer(bio)imagingtechniques,suchasmagneticresonancediffusiontensorimagingordiffusiontensortractography,areunderfurtherstudytodetectmicrostructuralabnormalitiesinthevisualpathwaythatcanpredictvisualfunctionbutdonotyethaveanestablishedroleinroutinesurveillance,particularlygiventheneedforsedationinyoungerpatients.Inaddition,otheremergingnoveltechnologies,suchasopticalcoherencetomography(OCT;refs.62,63),areevenmorepromisingandmayenableearlydetectionofopticnervedamage,especiallyinearlychildhoodwhenophthalmologicexaminationisdifﬁcult.OCTmeasuresthewidthoftheretinaandcanmeasurenervelossevenbeforethatismeasurablebyvisionassessment.TheOCTtechnologyisevolving,andnewerhandheldspectraldomainOCTdevicesthatpartiallyaccountfordifferencesinaxiallengthoftheeyeinchildrenhaveledtoincreasedenthusiasmforuseofOCTinmonitoringneuroﬁbromatosis-relatedopticnervepathology,althoughtheneedforsedationinyoungerpatientslimitsitsuniversalapplication.AlthoughOCTdataareencouraging,itisnotyetreadytobeaddedasarobusttoolforvisualsurveillanceinyoungchildrenwithNF1.Similarly,thereisnotenoughevi-dencetorecommendtheuseofvisualevokedpotentialsasascreeningtoolinOPG.CliniciansshouldbeawarethattheriskofotherCNStumors,althoughlow(1%–2%),isstillmuchhigherthaninthegeneralpopulation.Inchildhood,theyareusuallylow-gradegliomas,areoftenlocatedintheposteriorfossa(brain-stemandcerebellum),andhavealowgrowthrate.Mostofthemdonotproduceprogressivesymptoms,butfamiliesshouldbeinformedabouttheclinicalwarningsigns.Acom-prehensiveannualhistoryandneurologicexaminationmaybeusefulindetectingtheselesions.Thisriskofothermalignanttumorsinchildhood,includingMPNST,isgenerally<1%and,therefore,belowthethresholdtosuggestclinicalbeneﬁtbysurveillance(Table2).However,parentsshouldbealertedtothepotentialformalignanttransformationofexistingplexi-formneuroﬁbromasduringadolescence.Nonetheless,ifnewemergingtherapies,suchasMEKinhibitors,showbeneﬁts(theyalreadydoforbenignplexiforms)additionaltotumortreatment,thenearlierdetectionmaywellbewarranted.Surveillance1.Annualhistoryandphysicalexam[includingskinandneurologicexam,andalsobloodpressure(renalarterystenosis/pheochromocytomarisk),height,weight,andpubertaldevelopment].2.Ophthalmicassessment[detailedophthalmologicprotocol(ideallyinspecialistcenter);refs.51,64].3.AssesswithhistoryandclinicalexaminationannuallyfortypicalsignsofMPNST:anynondermalneuroﬁbromawithrapidgrowth,lossofneurologicfunction,orincreasingpainorchangeinconsistency.HaveincreasedsuspicioninthosewithfeaturesinTable4.Youngchildrendonotcomplainofvisualimpairmentuntilitisadvancedandsometimesonlywhentheyhavebilateralvisualloss.Parentsneedtobealerttopossiblesignsofvisualproblemssuchasfailuretopickupsmalltoysandbumpingintoobjects.Furthermore,visualassessmentisoftenproblem-aticinthosewithcognitivedeﬁcits.Quantitativetestingmethods(telleracuitycards)existforchildrenasyoungas6monthsofageandarereliablemeasuresofvisualacuity(VA;ref.65).Inolderchildren(usuallyatdevel-opmentalageof3years),testingmethodsmeasuretheabilitytorecognize("recognitionacuity")aﬁgure(e.g.,Leasymbols)orletters(e.g.,HOTVorSnellen).Colorvisioncanbeobtainedat5yearsandcomprehensiveperipheralvisualﬁeldsat8years(whereasmorebasicconfrontationvisualﬁeldscanbeobtainedmuchearlier).Besidesvisionlossandproptosis,OPGcanalsopresentasendocrinedisturbances(precociousordelayedpuberty,increasedgrowthvelocity)orhydrocephalus,andphysiciansshouldbeawareofthepossibilityofanunderlyingOPGifanyoftheseoccur.SurveillanceforOPGshould,therefore,include:*Sixto12monthlyophthalmicassessmentsfrombirthto8years(63,65),includingobjectiveandquantitativeVA[telleracuitycardsandwhenthechildismatureenoughforamorereliableVAtesting(e.g.,HOTV)],confrontationvisualﬁelds,pupillaryreﬂexes,andfundusexam.Every1to2yearsthereafteruntil20yearsofage.*Onebaselineassessmentofcolorvisionandvisualﬁeldsshouldbeundertakenwhenthechildismatureenoughtocopewiththetest.*Inspecializedsettingswhereavailable,OCTineveryophthalmologicassessmentmaybeconsideredasanobjectivemeasureofaxonalintegrity/axonallossandthicknessofretinalnerveﬁberlayer.*Duringscreening,ifavisionlossisdetected,andonceothercausesareexcluded(refractiveerror,opacities,etc.),arepeatedtestin2weeksshouldbeobtained.Ifvisionlosspersists,anMRIwouldbeindicated.Table4.FeaturesthatshouldheightenawarenessaboutlikelihoodofMPNSTFeatureHowtoassessLargeinternalnodularneuroﬁbromaburdenWhole-bodyMRIHardandpainfulsubcutaneousneuroﬁbroma(s)ClinicalhistoryandexaminationPreviouslyirradiatedbodyregionClinicalhistoryGermlineNF1microdeletionincludingSUZ12MutationtestingAtypicalneuroﬁbroma(neuroﬁbromawithregionsofhypercellularityandnuclearatypia)PrevioushistoryandbiopsyAcutesymptom/signPainespeciallythatwakespersonatnightMRIandFDGPETFocalneurologicsign/lossoffunctionMRIandFDGPETRapidgrowthofaneuroﬁbromaorpartofaplexiformMRIandFDGPETNeuroﬁbromatosis1www.aacrjournals.orgClinCancerRes;23(12)June15,2017e51on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from OncediagnosedwithOPG[refertomultidisciplinaryteam(MDT)]:*Follow-upunderneuro-oncologyMDT*Mayrequirechemotherapytreatment,butradiotherapynotrecommended(29)*Threeto6monthlyMRIsRecommendationsfortransitiontoadulthoodYoungadultswithNF1shouldbecounseledonthefutureriskofMPNSTandthecardinalsigns.Womenages30to50shouldbeadvisedoftheincreasedbreastcancerrisksof4-to5-fold(39,66)andtoaccessextrabreastscreeningaccordingtoguidelinesformoderate(20%)lifetimeriskorhighriskifadditionalfamilyhistoryofbreastcancer.BecauseoftheriskofMPNSTbeingassociatedwithhighinternaltumorburden,whole-bodyMRIshouldbeconsideredbetweenages16and20yearstoassessthis(30–32,52,67).NF1-affectedindividualswithhighinternaltumorburdenand/orwholegenedeletions(52)shouldbereferredtoaspecialistNF1networkclinicforlong-termfollow-upandsurveillance.AlladultswithNF1shouldhaveatleastannualbloodpressurechecksandaccesstospecialistclinicsiftheydevelopcardinalfeaturesofMPNST,gastrointestinalstromaltumors,orotherNF1-relatedmajorcomplications.ConclusionsThisreportmakesanumberofrecommendationsforthediagnosisandsurveillanceofchildrenandyoungadultswithNF1,whicharesummarizedinTable3.DisclosureofPotentialConﬂictsofInterestS.E.Plonisaconsultant/advisoryboardmemberforBaylorGenet-ics.Nopotentialconﬂictsofinterestweredisclosedbytheotherauthors.ReceivedMarch1,2017;revisedApril28,2017;acceptedMay2,2017;publishedonlineJune15,2017.References1.CushingH.Tumoursofthenervusacusticusandthesyndromeofthecerebello-pontineangle.Philadelphia:W.B.Saunders;1917.2.CroweFW,SchullWJ,NealJV,editors.Aclinicalpathologicalandgeneticstudyofmultipleneuroﬁbromatosis.Springﬁeld(IL):CharlesC.Thomas;1956.3.SeizingerBR,RouleauGA,OzeliusLG,LaneAH,FaryniarzAG,ChaoMV,etal.GeneticlinkageofvonRecklinghausenneuroﬁbromatosistothenervegrowthfactorreceptorgene.Cell1987;49:589–94.4.RouleauG,WerteleckiW,HainesJL,HobbsWJ,TrofatterJA,SeizingerBR,etal.GeneticlinkageanalysisofbilateralacousticneuroﬁbromatosistoaDNAmarkeronchromosome22.Nature1987;329:246–8.5.Nationalinstitutesofhealthconsensusdevelopmentconferencestatementonneuroﬁbromatosis.ArchNeurol1987;45:575–9.6.ViskochilD,BuchbergAM,XuG,CawthonRM,StevensJ,WolffRK,etal.Deletionsandatranslocationinterruptaclonedgeneattheneuroﬁbro-matosistype1locus.Cell1990;62:187–92.7.TroffaterJA,MacCollinMM,RutterJL,MurrellJR,DuyaoMP,ParryDM,etal.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneuroﬁbromatosis2tumorsuppressor.Cell1993;72:791–800.8.RouleauGA,MerelP,LutchmanM,SansonM,ZucmanJ,MarineauC,etal.Alterationinanewgeneencodingaputativemembrane-orga-nizingproteincausesneuro-ﬁbromatosistype2.Nature1993;363:515–21.9.NarodSA,ParryDM,ParboosinghJ,LenoirGM,RuttledgeM,FischerG,etal.Neuroﬁbromatosistype2appearstobeageneticallyhomogenousdisease.AmJHumGenet1992;51:486–96.10.UpadhyayaM,HusonSM,DaviesM,ThomasN,ChuzhanovaN,Gio-vanniniS,etal.Anabsenceofcutaneousneuroﬁbromasassociatedwitha3-bpin-framedeletioninexon17oftheNF1gene(c.2970_2972delAAT):EvidenceofaclinicallysigniﬁcantNF1genotype-phenotypecorrelation.AmJHumGenet2007;80:140–51.11.BremsH,ChmaraM,SahbatouM,DenayerE,TaniguchiK,KatoR,etal.Germlineloss-of-functionmutationsinSPRED1causeaneuroﬁbromato-sis1-likephenotype.NatGenet2007;39:1120–6.12.MacCollinM,WoodﬁnW,KronnD,ShortMP.Schwannomatosis:aclinicalandpathologicstudy.Neurology1996;46:1072–9.13.MacCollinM,WillettC,HeinrichB,JacobyLB,AciernoJSJr,PerryA,etal.Familialschwannomatosis:exclusionoftheNF2locusasthegermlineevent.Neurology2003;60:1968–74.14.HulsebosTJ,PlompAS,WoltermanRA,Robanus-MaandagEC,BaasF,WesselingP.GermlinemutationofINI1/SMARCB1infamilialschwan-nomatosis.AmJHumGenet2007;80:805–10.15.TaboriU,HansfordJR,AchatzMI,KratzCP,PlonSE,FrebourgT,etal.Clinicalmanagementandtumorsurveillancerecommendationsofinher-itedmismatchrepairdeﬁciencyinchildhood.ClinCancerRes2017;23:e32–e37.16.HusonSM,HarperPS,CompstonDA.VonRecklinghausenneuroﬁbro-matosis.Aclinicalandpopulationstudyinsouth-eastWales.Brain1988;111:1355–81.17.McGaughranJM,HarrisDI,DonnaiD,TeareD,MacLeodR,WesterbeekR,etal.Aclinicalstudyoftype1neuroﬁbromatosisinNorthWestEngland.JMedGenet1999;36:192–6.18.ZvulunovA,BarakY,MetzkerA.Juvenilexanthogranuloma,neuroﬁbro-matosis,andjuvenilechronicmyelogenousleukemia.Worldstatisticalanalysis.ArchDermatol1995;131:904–8.19.FernerRE,GutmannDH.Neuroﬁbromatosistype1(NF1):diagnosisandmanagement.HandbClinNeurol2013;115:939–55.20.EvansDG,HowardE,GiblinC,ClancyT,SpencerH,HusonSM,etal.Birthincidenceandprevalenceoftumourpronesyndromes:estimatesfromaUKgeneticfamilyregisterservice.AmJMedGenet2010;152A:327–32.21.UusitaloE,Lepp€avirtaJ,KoffertA,SuominenS,VahteraJ,VahlbergT,etal.Incidenceandmortalityofneuroﬁbromatosis:atotalpopulationstudyinFinland.JInvestDermatol2015;135:904–6.22.GartyBZ,LaorA,DanonYL.Neuroﬁbromatosistype1inIsrael:surveyofyoungadults.JMedGenet1994;31:853–7.23.MessiaenLM,CallensT,MortierG,BeysenD,VandenbrouckeI,VanRoyN,etal.ExhaustivemutationanalysisoftheNF1geneallowsidentiﬁcationof95%ofmutationsandrevealsahighfrequencyofunusualsplicingdefects.HumMutat2000;15:541–55.24.SabbaghA,PasmantE,ImbardA,LuscanA,SoaresM,BlancheH,etal.NF1molecularcharacterizationandneuroﬁbromatosistypeIgenotype-phe-notypecorrelation:theFrenchexperience.HumMutat2013;34:1510–8.25.ProsE,GomezC,MartínT,FabregasP,SerraE,LazaroC.NatureandmRNAeffectof282differentNF1pointmutations:focusonsplicingalterations.HumMutat2008;29:E173–93.26.EvansDG,BowersN,Burkitt-WrightE,MilesE,GargS,Scott-KitchingV,etal.ComprehensiveRNAanalysisoftheNF1geneinclassicallyaffectedNF1affectedindividualsmeetingNIHcriteriahashighsensitivityandmutationnegativetestingisreassuringinisolatedcaseswithpigmentaryfeaturesonly.eBioMedicine2016;7:212–20.27.WimmerK,RosenbaumT,MessiaenL.Connectionsbetweenconstitu-tionalmismatchrepairdeﬁciencysyndromeandneuroﬁbromatosistype1.ClinGenet2017;91:507–19.28.EastonDF,PonderMA,HusonSM,PonderBAJ.Ananalysisofvariationinexpressionofneuroﬁbromatosis(NF1):evidenceofmodifyinggenes.AmJHumGenet1993;53:305–13.29.SharifS,FernerR,BirchJ,GattamaneniR,GillespieJ,EvansDGR.SecondprimarytumoursinNeuroﬁbromatosis1(NF1)patientstreatedClinCancerRes;23(12)June15,2017ClinicalCancerResearche52CCRPEDIATRICONCOLOGYSERIESon June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from foropticglioma:substantialriskspostradiotherapy.JClinOncol2006;24:2570–5.30.NguyenR,JettK,HarrisGJ,CaiW,FriedmanJM,MautnerVF.Benignwholebodytumorvolumeisariskfactorformalignantperipheralnervesheathtumorsinneuroﬁbromatosistype1.JNeurooncol2014;116:307–13.31.MautnerVF,AsuagborFA,DombiE,F€unstererC,KluweL,WenzelR,etal.Assessmentofbenigntumorburdenbywhole-bodyMRIinpatientswithneuroﬁbromatosis1.NeuroOncol2008;10:593–8.32.TuckerT,WolkensteinP,RevuzJ,ZellerJ,FriedmanJM.AssociationbetweenbenignandmalignantperipheralnervesheathtumorsinNF1.Neurology2005;65:205–11.33.ListernickR,CharrowJ,GreenwaldMJ,EsterlyNB.Opticgliomasinchildrenwithneuroﬁbromatosistype1.JPediatr1989;114:788–92.34.SinghalS,KerrB,BirchJ,LashfordL,EvansDGR.ClinicalcharacteristicsofsymptomaticsporadicandNF1relatedopticgliomata:implicationsformanagement.ArchDisChild2002;87:65–70.35.RodriguesACJr,Ferraz-FilhoJR,TorresUS,daRochaAJ,MunizMP,SouzaAS,etal.Ismagneticresonancespectroscopycapableofdetectingmetabolicabnormalitiesinneuroﬁbromatosistype1thatarenotrevealedinbrainparenchymaofnormalappearance?PediatrNeurol2015;52:314–9.36.RoyA,BarbarotS,CharbonnierV,Gayet-DelacroixM,StalderJF,RoulinJL,etal.Examiningthefrontalsubcorticalbrainvulnerabilityhypothesisinchildrenwithneuroﬁbromatosistype1:areT2-weightedhyperintensitiesrelatedtoexecutivedysfunction?Neuropsychology2015;29:473–84.37.Ferraz-FilhoJR,JosedaRochaA,MunizMP,SouzaAS,Goloni-BertolloEM,Pavarino-BertelliEC.Unidentiﬁedbrightobjectsinneuroﬁbroma-tosistype1:conventionalMRIinthefollow-upandcorrelationofmicrostructurallesionsondiffusiontensorimages.EurJPaediatrNeurol2012;16:42–7.38.EvansDGR,BaserME,McGaughranJ,SharifS,DonnellyB,MoranA.Malignantperipheralnervesheathtumoursinneuroﬁbromatosis1.JMedGenet2002;39:311–4.39.UusitaloE,RantanenM,Kallionp€a€aRA,P€oyh€onenM,Lepp€avirtaJ,Yl€a-OutinenH,etal.Distinctivecancerassociationsinpatientswithneuro-ﬁbromatosistype1.JClinOncol2016;34:1978–86.40.EvansDG,HowardE,WildingA,InghamSL,MoranA,Scott-KitchingV,etal.Mortalityinneuroﬁbromatosis1.EurJHumGenet2011;19:1187–91.41.FernerRE,LucasJD,O'DohertyMJ,HughesRA,SmithMA,CroninBF,etal.Evaluationof(18)ﬂuorodeoxyglucosepositronemissiontomography((18)FDGPET)inthedetectionofmalignantperipheralnervesheathtumoursarisingfromwithinplexiformtumoursinneuroﬁbromatosis1.JNeurolNeurosurgPsychiat2000;68:353–7.42.WarbeyVS,FernerRE,DunnJT,CalonjeE,O'DohertyMJ.[18F]FDGPET/CTinthediagnosisofmalignantperipheralnervesheathtumoursinneuroﬁbromatosistype-1.EurJNuclMedMolImaging2009;36:751–7.43.TsaiLL,DrubachL,FaheyF,IronsM,VossS,UllrichNJ.[18F]-Fluorodeox-yglucosepositronemissiontomographyinchildrenwithneuroﬁbroma-tosistype1andplexiformneuroﬁbromas:correlationwithmalignanttransformation.JNeurooncol2012;108:469–75.44.BrahmiM,ThiesseP,RanchereD,MognettiT,PinsonS,RenardC,etal.DiagnosticaccuracyofPET/CT-guidedpercutaneousbiopsiesformalig-nantperipheralnervesheathtumorsinneuroﬁbromatosistype1patients.PLoSOne2015;10:e0138386.45.PatilS,ChamberlainRS.NeoplasmsassociatedwithgermlineandsomaticNF1genemutations.Oncologist2012;17:101–16.46.CrucisA,RicherW,BrugieresL,BergeronC,Marie-CardineA,StephanJL,etal.RhabdomyosarcomasinchildrenwithneuroﬁbromatosistypeI:anationalhistoricalcohort.PediatrBloodCancer2015;62:1733–8.47.DeSmetL,SciotR,LegiusE.Multifocalglomustumoursoftheﬁngersintwopatientswithneuroﬁbromatosistype1.JMedGenet2002;39:e45.48.GutmannDH,AylesworthA,CareyJC,KorfB,MarksJ,PyeritzRE,etal.Thediagnosticandmulti-disciplinarymanagementofneuroﬁbromatosis1andneuroﬁbromatosis2.JAMA1997;278:51–7.49.CassimanC,LegiusE,SpileersW,CasteelsI.Ophthalmologicalassess-mentofchildrenwithneuroﬁbromatosistype1.EurJPediatr2013;172:1327–33.50.FernerRE,HusonS,ThomasN,MossC,WillshawH,EvansDG,etal.GuidelinesforthediagnosisandmanagementofIndividualswithNeu-roﬁbromatosis1(NF1).JMedGenet2007;44:81–8.51.FisherMJ,AveryRA,AllenJC,Ardern-HolmesSL,BilaniukLT,FernerRE,etal.FunctionaloutcomemeasuresforNF1-associatedopticpathwaygliomaclinicaltrials.Neurology2013;81:S15–24.52.DeRaedtT,BremsH,WolkensteinP,VidaudD,PilottiS,PerroneF,etal.ElevatedriskforMPNSTinNF1microdeletionpatients.AmJHumGenet2003;72:1288–92.53.UpadhyayaM,HusonSM,DaviesM,ThomasN,ChuzhanovaN,Gio-vanniniS,etal.Anabsenceofcutaneousneuroﬁbromasassociatedwitha3-bpin-framedeletioninexon17oftheNF1gene(c.2970_2972delAAT):EvidenceofaclinicallysigniﬁcantNF1genotype-phenotypecorrelation.AmJHumGenet2007;80:140–51.54.RojnueangnitK,XieJ,GomesA,SharpA,CallensT,ChenY,etal.HighincidenceofnoonansyndromefeaturesincludingshortstatureandpulmonicstenosisinpatientscarryingNF1missensemutationsaffect-ingp.Arg1809:genotype-phenotypecorrelation.HumMutat2015;36:1052–63.55.Ben-ShacharS,ConstantiniS,HalleviH,SachEK,UpadhyayaM,EvansGD,etal.Increasedrateofmissense/in-framemutationsinindividualswithNF1-relatedpulmonarystenosis:anovelgenotype-phenotypecorre-lation.EurJHumGenet2013;21:535–9.56.BurkittWrightEM,SachE,SharifS,QuarrellO,CarrollT,WhitehouseRW,etal.CanthediagnosisofNF1beexcludedclinically?Alackofpigmentaryﬁndingsinfamilieswithspinalneuroﬁbromatosisdemonstratesalimi-tationofclinicaldiagnosis.JMedGenet2013;50:606–13.57.DombiE,BaldwinA,MarcusLJ,FisherMJ,WeissB,KimA,etal.Activityofselumetinibinneuroﬁbromatosistype1-relatedplexiformneuroﬁbromas.NEnglJMed2016;375:2550–60.58.WimmerK,KratzCP,VasenHF,CaronO,ColasC,Entz-WerleN,etal.EU-ConsortiumCareforCMMRD(C4CMMRD).Diagnosticcriteriaforcon-stitutionalmismatchrepairdeﬁciencysyndrome:suggestionsoftheEuro-peanconsortium'careforCMMRD'(C4CMMRD).JMedGenet2014;51:355–65.59.RadtkeHB,SeboldCD,AllisonC,HaidleJL,SchneiderG.Neuroﬁ-bromatosistype1ingeneticcounselingpractice:recommendationsoftheNationalSocietyofGeneticCounselors.JGenetCouns2007;16:387–407.60.AmericanAcademyofPediatrics.Ethicalandpolicyissuesingenetictestingandscreeningofchildren.Pediatrics2013;131:620–2.61.YorczykA,RobinsonLS,RossTS.Useofpaneltestsinplaceofsinglegenetestsinthecancergeneticsclinic.ClinGenet2015;88:278–82.62.AveryRA,CnaanA,SchumanJS,ChenCL,GlaugNC,PackerRJ,etal.Intra-andinter-visitreproducibilityofganglioncell-innerplexiformlayermea-surementsusinghandheldopticalcoherencetomographyinchildrenwithopticpathwaygliomas.AmJOphthalmol2014;158:916–23.63.LeeH,ProudlockFA,GottlobI.Pediatricopticalcoherencetomographyinclinicalpractice-recentprogress.InvestOphthalmolVisSci2016;57:69–79.64.CaenS,CassimanC,LegiusE,CasteelsI.Comparativestudyoftheophthalmologicalexaminationsinneuroﬁbromatosistype1.Pro-posalforanewscreeningalgorithm.EurJPaediatrNeurol2015;19:415–22.65.FisherMJ,AveryRA,AllenJC,Ardern-HolmesSL,BilaniukLT,FernerRE,etal.FunctionaloutcomemeasuresforNF1-associatedopticpathwaygliomaclinicaltrials.Neurology2013;81(21Suppl1):S15–S24.66.SharifS,MoranA,HusonSM,IddendenR,ShentonA,HowardE,etal.WomenwithNeuroﬁbromatosis1(NF1)areatamoderatelyincreasedriskofdevelopingbreastcancerandshouldbeconsideredforearlyscreening.JMedGenet2007;44:481–4.67.AhlawatS,FayadLM,KhanMS,BredellaMA,HarrisGJ,EvansDG,etal.Currentwhole-bodyMRIapplicationsintheneuroﬁbromatoses:NF1,NF2,andschwannomatosis.Neurology2016;87:S31–9.www.aacrjournals.orgClinCancerRes;23(12)June15,2017e53Neuroﬁbromatosis1on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 2017;23:e46-e53. Clin Cancer Res(cid:160)(cid:160) D. Gareth R. Evans, Hector Salvador, Vivian Y. Chang, et al. (cid:160) Pediatric Neurofibromatosis 1Cancer and Central Nervous System Tumor Surveillance in(cid:160) Updated version(cid:160)  http://clincancerres.aacrjournals.org/content/23/12/e46Access the most recent version of this article at:(cid:160) (cid:160) (cid:160) (cid:160) (cid:160) Cited articles(cid:160)  http://clincancerres.aacrjournals.org/content/23/12/e46.full.html#ref-list-1This article cites 65 articles, 17 of which you can access for free at:(cid:160) (cid:160) (cid:160) E-mail alerts related to this article or journal.Sign up to receive free email-alerts(cid:160) SubscriptionsReprints and (cid:160) .pubs@aacr.orgTo order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at(cid:160) Permissions(cid:160) .permissions@aacr.orgTo request permission to re-use all or part of this article, contact the AACR Publications Department aton June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 